SEC filings and other documents

Strong Q1 growth and upgraded 2026 guidance driven by travel health and new BARDA contract.

2025 revenue hit DKK 6.2 billion, driven by travel health and public preparedness growth.

Revenue up 32% to DKK 4.8B, strong margins, and robust vaccine growth drive outlook.

Strong revenue growth, robust margins, and a recommended takeover offer at a premium.

33% revenue growth and 32% EBITDA margin in H1 2025, with refined guidance and takeover offer.

Robust growth, new vaccine launches, and strategic initiatives drive strong outlook.

Q1 revenue up 62% with strong margins and robust outlook, led by travel health and preparedness.

2024 saw record revenue and margins, with strong outlook and new vaccine launches ahead.

Vaccine supply, portfolio growth, and new launches drive strong outlook and global expansion.

Strong Q3 results and upgraded 2024 guidance driven by robust vaccine demand and order intake.

H1 revenue reached DKK 2.3B, with top-end 2024 guidance confirmed and mpox capacity expansion planned.